Abstracts

Post-COVID Conditions Following COVID-19 Vaccination: A Matched Analysis of Patients With SARS-CoV-2

Background: COVID-19 vaccinations protect against severe illness and death, but associations with post-COVID conditions (PCC) are less clear. We aimed to evaluate the association between prior vaccination and new-onset PCC among individuals with SARS-CoV-2 infection across eight large healthcare systems in the United States. Methods: This study was a retrospective matched cohort study using electronic…

Evaluating the Effect of Vaccination on Post-COVID Conditions Among Patients With and Without HIV

Background: Previous studies have described conditions presenting post-acute SARS-CoV-2 (COVID) infection, known as Post-COVID Conditions (PCC) or as Long COVID; but the effect of vaccination, especially among immunocompromised patients, is unclear. We evaluated the effect of COVID-19 vaccination on PCC within an integrated health system (Kaiser Permanente Mid-Atlantic States; KPMAS), for patients with HIV (PWH)…

Anti-α4β7 Antibody Facilitates Improved Renal Function During SIV Infection in Macaques

Background: Combination antiretroviral therapy (cART) reduces the incidence of HIV-associated nephropathy (HIVAN), but people living with HIV (PLWH) remain at high risk for later developing chronic kidney disease (CKD), with a poorly defined etiology. HIV acquisition is associated with reduced plasma all-trans-retinoic acid (atRA) and increased pro-fibrotic galectin (Gal)-3. Clinical trials investigating atRA receptor agonists…

Urinary Exosome-Derived MicroRNAs as Biomarkers of TDF Renal Toxicity in People Living With HIV

Background: The use of tenofovir disoproxil fumarate (TDF) may produce tubular proximal renal toxicity, but severity and outcome is controversial and specific biomarkers are still required. The aim of this study was to evaluate the expression profiles of urinary exosome-derived microRNA (miR) as biomarkers of TDF-associated renal toxicity. Methods: In a longitudinal study, urine samples…

Impact of Raltegravir Intensification on the Gut Microbiota of People With Chronic HIV-1 Infection

Background: Chronic human immunodeficiency virus 1 (HIV-1) infection is associated with gut microbiota alterations, including low gene richness and shifts in certain bacterial species, which have been linked to immune dysfunction. Residual HIV-1 replication might contribute to perpetuating such gut dysbiosis. We sought to explore if antiretroviral treatment (ART) intensification with raltegravir (RAL) had the…

Phase 4 DEFINE Switch Study to Manage InSTI-related Weight Gain: Metabolics and Biomarker Analysis

Background: Integrase strand transfer inhibitor (INSTI)–based antiretroviral therapies are associated with greater weight gain than non-nucleoside reverse transcriptase inhibitor– or boosted protease inhibitor (PI)–based regimens, and these effects disproportionately impact Black and Hispanic individuals and women living with HIV-1. DEFINE is the first prospective, randomized trial to explore the impact of switching from an INSTI-based…